Logo image of LABP

LANDOS BIOPHARMA INC (LABP) Stock Analyst Ratings

USA - Nasdaq - NASDAQ:LABP - US5150692011 - Common Stock

22.93 USD
+0.13 (+0.58%)
Last: 5/23/2024, 8:16:35 PM
22.91 USD
-0.02 (-0.09%)
After Hours: 5/23/2024, 8:16:35 PM
Buy % Consensus

48

ChartMill assigns a Buy % Consensus number of 48% to LABP. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 12.96. This target is -43.46% below the current price.
LABP was analyzed by 8 analysts. The buy percentage consensus is at 48. So analysts seem to be rather neutral about LABP.
In the previous month the buy percentage consensus was at a similar level.
LABP was analyzed by 8 analysts. More opinions would make the average more meaningful.

Related screens

LABP Historical Analyst RatingsLABP Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -37 -33 -29 -25 -21 -17 -13 -9 -5 -1 2 4 6 8 10

Price Target & Forecast

Price Low Median Mean High 22.935.0512.9612.9621.44 - -77.98% -43.46% -43.46% -6.49%

Related screens

LABP Current Analyst RatingLABP Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 1 2 3 4
Up and Down Grades
Date Firm Action Rating
2024-04-01 HC Wainwright & Co. Downgrade Buy -> Neutral
2023-01-06 Jefferies Downgrade Hold -> Underperform
2022-11-11 SVB Leerink Maintains Market Perform
2022-08-12 SVB Leerink Maintains Market Perform
2022-08-12 Raymond James Downgrade Outperform -> Market Perform
2022-04-12 Jefferies Downgrade Buy -> Hold
2022-01-03 JP Morgan Maintains Neutral
2021-11-16 SVB Leerink Downgrade Outperform -> Market Perform
2021-10-20 Craig-Hallum Initiate Buy
2021-10-19 HC Wainwright & Co. Initiate Buy
2021-09-23 JonesTrading Initiate Buy
2021-07-30 Raymond James Maintains Outperform
2021-03-01 SVB Leerink Initiate Outperform
2021-03-01 Raymond James Maintains Outperform
2021-03-01 JP Morgan Initiate Neutral
2021-03-01 Jefferies Initiate Buy

LANDOS BIOPHARMA INC / LABP FAQ

What do analysts expect the price target to be for LANDOS BIOPHARMA INC (LABP)?

8 analysts have analysed LABP and the average price target is 12.96 USD. This implies a price decrease of -43.46% is expected in the next year compared to the current price of 22.93.


What is the consensus rating for LANDOS BIOPHARMA INC (LABP) stock?

The consensus rating for LANDOS BIOPHARMA INC (LABP) is 47.5 / 100 . This indicates that analysts generally have a neutral outlook on the stock.